JHEP Reports

Article	Citations
Increased carbohydrate deficient transferrin: Whisky or candy?	176
Reply to: “Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans”	161
Reply to: “The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites”	124
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice	119
Copyright and information	115
The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD	114
Erratum to “Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis” [JHEP Reports 6 (2024) 100949]	110
Reply to: “Dynamic imaging of macrophages in MASLD: A major interest in insulin resistance and outside the liver”	90
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool	77
Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer	73
Identifying emergency presentations of chronic liver disease using routinely collected administrative hospital data	73
Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging	65
JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication	61
Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?	59
Emerging roles of circular RNAs in liver cancer	58
Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation	56
Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis	56
Epigenetics of alcohol-related liver diseases	54
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association	53
Protective role of physical activity against HCC risk in type 2 diabetes: Evidence and public health perspectives	51
Copyright and information	50
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort st	46
Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis	46
A small animal model of chronic hepatitis E infection using immunocompromised rats	44
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis	43

Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis	42
Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis	41
External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort	41
Predicting liver ablation volumes with real-time MRI thermometry	40
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates	40
Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes	40
Editorial Board page	39
Copyright and information	38
Potential role of liver-resident CD3+ macrophages in HBV clearance in a mouse hepatitis B model	38
Xanthine oxidase promotes hepatic lipid accumulation through high fat absorption by the small intestine	37
Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF	36
All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study	36
Reply to: “Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?”	35
SARS-CoV-2 receptor ACE2 is upregulated by fatty acids in human MASH	35
Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis	34
Predicting the need for early TIPS in patients with cirrhosis and ascites: more art than science.	33
Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey	33
Understanding virologic heterogeneity in chronic hepatitis B treatment	32
Editorial Board page	32
HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV	32
Contents	32
Editorial Board page	31
Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment	31
Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice	31
Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency	31
Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis	30
A novel therapy targeting the gut–liver axis for chronic hepatitis B: Ursodeoxycholic acid plus Bifidobacterium	30
Arachidonic acid activates NLRP3 inflammasome in MDSCs via FATP2 to promote post-transplant tumour recurrence in steatotic liver grafts	30
p53 and TIGAR promote redox control to protect against metabolic dysfunction-associated steatohepatitis	30
PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle	30
Ablation of liver Fxr results in an increased colonic mucus barrier in mice	30
Deep learning can predict cardiovascular events from liver imaging	30
Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection	30
Contents	29
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis	29
Corrigendum to: ‘Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia’ (JHEP Reports, Volume 6, Issue 7, July 2024, 101090)	28
Dual-tracer PET/CT in the management of hepatocellular carcinoma	28
Monitoring of hepatitis E virus infection and replication by functional tagging of the ORF2 protein	28
Reply to: “Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma”	28
Application of a deep learning algorithm for the diagnosis of HCC	27
Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy	27
Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection	27
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis	26
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation	26
Non-invasive biomarkers of Fontan-associated liver disease	26
Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology	26
Regulatory T cell therapy in autoimmune liver disease and transplantation	26
Editorial Board page	25
Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity	25
Reply to: “Trans-splenic anterograde coil assisted transvenous obliteration vs. retrograde transvenous obliteration: Are we heading the right way?”	25

Hepatocyte proteomes reveal the role of protein disulfide isomerase 4 in alpha 1-antitrypsin deficiency	25
Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries	24
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆	24
Outcomes of 38 patients with PFIC3: Impact of genotype and of response to ursodeoxycholic acid therapy	24
CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis	24
Minimal residual ascites 3 months after TIPS implantation implicates worse clinical outcomes in patients with cirrhosis	24
Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis	24
Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet	24
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma	24
Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure	23
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab	23
Cholangiocarcinoma-on-a-chip: A human 3D platform for personalised medicine	23
Editorial Board page	23
A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma	22
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies	22
A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis	22
Does ammonia really disrupt brain oxygen homeostasis?	22
Corrigendum to ‘A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation’ [JHEP Reports 6	22
Myeloid TGF-beta signaling shapes liver macrophage heterogeneity and metabolic liver disease pathogenesis	22
The role of cGAS-STING signalling in liver diseases	22
Good long-term outcomes of primary sclerosing cholangitis in childhood	22
Serum proteomics of adults with acute liver failure provides mechanistic insights and attractive prognostic biomarkers	21
Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma	21
Reply to: “Combined heart-liver transplantation for congestive hepatopathy with bridging fibrosis: Is it warranted?”	21
Small molecule drugs promote repopulation of transplanted hepatocytes by stimulating cell dedifferentiation	21
Excellent outcomes with liver transplantation in hepatopulmonary syndrome across pre-transplant PaO2 spectrum	21
Resolvin D1-mediated cellular crosstalk protects against MASH	20
Prevalence of Rocahepevirus ratti (rat hepatitis E virus) in humans and rats in China	20
Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis	20
Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort	20
Bile acids contribute to the development of non-alcoholic steatohepatitis in mice	20
Guideline-Enhanced Large Language Models Outperforms Physician-Test Takers on EASL Campus Quizzes Multiple Choice Questions	20
Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: A systematic review and meta-analysis	20
Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors	20
QuickStroop for screening for minimal hepatic encephalopathy in patients with cirrhosis	19
Evolving epidemiology of HCC in Spain	19
Hepatic microbiome in healthy lean and obese humans	19
Acknowledging our reviewers	19
Should all pediatric patients with type 1 autoimmune hepatitis be screened for inflammatory bowel disease?	19
High precision-cut liver slice model to study cell-autonomous antiviral defense of hepatocytes within their microenvironment	19
Pravastatin reduces all-cause mortality in elderly individuals at risk of liver fibrosis: Post hoc analysis of the PROSPER trial	19
Copyright and information	19
DHCR7 inhibition ameliorates MetALD and HCC in mice and human 3D liver spheroids	19
LAPTM4B enhances the stemness of CD133+ liver cancer stem-like cells via WNT/β-catenin signaling	18
Embedding assessment of liver fibrosis into routine diabetic review in primary care	18
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison	18
Thyroid dysfunction in MASLD: Results of a nationwide study	18
Transcriptomics unveils immune metabolic disruption and a novel biomarker of mortality in patients with HBV-related acute-on-chronic liver failure	17
Circadian control of ConA-induced acute liver injury and inflammatory response via Bmal1 regulation of Junb	17
Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis	17
Estimating the clinical prevalence of Wilson’s disease in the UK	17
Whole blood RNA sequencing identifies transcriptional differences between primary sclerosing cholangitis and ulcerative colitis	17
Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis	17
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis	17
Sarcopenia-related gut microbial changes are associated with the risk of complications in people with cirrhosis	17
Innovative approaches to the management of ascites in cirrhosis	17
Contents	17
Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice	16
Contents	16
Hepatic immune environment differences among common mouse strains in models of MASH and liver cancer	16
Genome-wide meta-analysis identifies nine loci to be associated with higher risk of hepatocellular carcinoma development.	16
Editorial Board page	16
Erratum to ‘Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease’ (JHEP Reports 5 [2023] 100836)	16
Traditional lifestyle factors partly mediate the association of socioeconomic position with intrahepatic lipid content: The Maastricht study	16
Editorial Board page	16
Corrigendum to ‘Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation’ [JHEP Reports 6 (2024) 100983]	16
Dyrk2 gene transfer suppresses hepatocarcinogenesis by promoting the degradation of Myc and Hras	16
Single-cell analysis of mature hepatocytes reveals an IRF1-driven restriction of HDV infection	15
Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis	15
Fructoholism in adults: The importance of personalised care in metabolic dysfunction-associated fatty liver disease	15
Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease	15
Response to Letter to the Editor “Statins in MASLD: Challenges and Future”	15
Distribution of non-ceruloplasmin-bound copper after i.v. 64Cu injection studied with PET/CT in patients with Wilson disease	15
Development and validation of a dynamic survival prediction model for patients with acute-on-chronic liver failure	15
Contents	15
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV	15
B4GALNT1 promotes hepatocellular carcinoma stemness and progression via integrin α2β1-mediated FAK and AKT activation	15
Downregulation of SOCS1 increases interferon-induced ISGylation during differentiation of induced-pluripotent stem cells to hepatocytes	15
Gut microbiome dynamics and Enterobacterales infection in liver transplant recipients: A prospective observational study	15
Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort	15

Reply to: Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy	15
Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation	15
Liver specification of human iPSC-derived endothelial cells transplanted into mouse liver	15
Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1	15
Editorial Board page	14
ABCB4 variant is associated with hepatobiliary MR abnormalities in people with low-phospholipid-associated cholelithiasis syndrome	14
MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis	14
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study	14
AI-Cirrhosis-ECG (ACE) score for predicting decompensation and liver outcomes	14
Transcriptomic landscapes of effective and failed liver regeneration in humans	14
Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component	14
Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD	14
Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease	14
Reconsidering low HDL-cholesterol levels as a predictive factor for the development of hepatocellular carcinoma	14
A missense variant in human perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice	14
Surveillance for hepatocellular carcinoma in patients with primary biliary cholangitis: For all or just for some?	14
Characterisation of forkhead box protein A3 as a key transcription factor for hepatocyte regeneration	14
Waiting time dictates impact of frailty: A Spanish multicenter prospective study	13
Contents	13
A machine learning-based classification of adult-onset diabetes identifies patients at risk of liver-related complications	13
Immunomodulatory receptor VSIG4 is released during spontaneous bacterial peritonitis and predicts short-term mortality	13
Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation	13
Characterisation of hepatic lipid signature distributed across the liver zonation using mass spectrometry imaging	13
New targets for NAFLD	13
SBRT for bridging and downstaging HCC before transplant	13
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort	13
Endoscopic ultrasound-guided portosystemic pressure gradient measurement vs. transjugular balloon occlusion measurement in patients with cirrhosis (ENCOUNTER): A bicentric EU study	13
Editorial Board page	13
Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease	13
NTCP ubiquitination enables Hepatitis B Virus (HBV) infection	13
Downregulation of hepatic METTL3 contributes to APAP-induced liver injury in mice	12
Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study	12
Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome	12
Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication	12
Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)	12
Rethinking Risk Indices in Pediatric MASLD	12
Editorial Board page	12
Hepatic venous pressure gradient in sinusoidal obstruction syndrome: Diagnostic value and link with histological lesions	12
Drug-induced liver injury in children: A nationwide cohort study from China	12
Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival	12
Contents	12
Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia	12
Infection prevention and control programme and COVID-19 measures: Effects on hospital-acquired infections in patients with cirrhosis	11
Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002–2022)	11
A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice	11
Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans	11
Copyright and information	11
Risk of portal hypertensive complications preventable by TIPS in patients with ascites	11
Reply to: “Ductular reaction is a prognostic factor in primary biliary cholangitis”	11
Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virus replication and assembly	11
Contents	11
Editorial Board page	11
Copyright and information	11
Ketamine restriction correlates with reduced cholestatic liver injury and improved outcomes in critically ill patients with burn injury	11
Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts	11
Inhibition of phospholipase D1 ameliorates hepatocyte steatosis and non-alcoholic fatty liver disease	11
Contents	11
Copyright and information	11
Impact of bacterial infections prior to liver transplantation on post-transplant outcomes in patients with cirrhosis	11
Histological and serological features of acute liver injury after SARS-CoV-2 vaccination	10
Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases	10
Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-/- mouse model of sclerosing cholangitis	10
Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis	10
C/EBPβ–VCAM1 axis in Kupffer cells promotes hepatic inflammation in MASLD	10
Clinical Burden of Hepatitis Delta Virus in Spain: Incidence, Prevalence, and Associated Comorbidities	10
AI-derived body composition parameters as prognostic factors in patients with HCC undergoing TACE in a multicenter study	10
Daytime napping, nighttime sleeping duration, and risk of hepatocellular carcinoma and liver disease-related mortality	10
Implementing a new HCV model of care for people who use drugs	10
Preoperative TIPS prevents the development of postoperative acute-on-chronic liver failure in patients with high CLIF-C AD score	10
Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease	10
Contents	10
Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case report	10
AI-based tumor-infiltrating lymphocyte scoring system for assessing HCC prognosis in patients undergoing liver resection	10
Copyright and information	10
Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis	10
Use of albumin infusion for cirrhosis-related complications: An international position statement	10
Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFNα non-response	10
A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation	10
Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis	10
Effect of plasma exchange with albumin replacement on albumin functionality and organ dysfunction in acute-on-chronic liver failure	10
Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts	10
Recompensation in patients with autoimmune hepatitis-related decompensated cirrhosis following immunosuppressive therapy	9
Macrophage-derived IL-15 imprints peritoneal TRM-like CD8 T cells in cirrhosis and spontaneous bacterial peritonitis	9
An international multicentre evaluation of treatment strategies for combined hepatocellular-cholangiocarcinoma✰	9
Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension: a randomized, single-blind clinical trial	9
Autoantibody formation against a canalicular epitope found in a patient with acute intrahepatic cholestasis with PFIC-like presentation	9
Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial	9
Hepatic stellate cell single cell atlas reveals a highly similar activation process across liver disease aetiologies	9
Reply to: “Comment on opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis”	9
Plasma proteomic signature for preoperative prediction of microvascular invasion in HCC	9
Stiffness-activated Hepatic Stellate Cells boost HCC Migration via TGM2/ITGB1-mediated Matrix Remodeling and Mitochondrial Transfer	9
Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions	9
Hepatocellular carcinoma risk scores for non-viral liver disease: A systematic review and meta-analysis	9
A comment on “Association of physical activity, including amount and maintenance, with the risk of HCC among patients with type 2 diabetes”	9
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab	9